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Regulation of ligand binding to glycoprotein lib-lila (integrin lbfl3)
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The major platelet integrin, glycoprotein lIb-Illa, binds soluble
fibrinogen only after platelet activation. To investigate the
mechanism by which platelets convert glycoprotein lb-Illa into
a functional fibrinogen receptor, we characterized the opening
and closing of fibrinogen-binding sites in isolated platelet mem-
branes and compared the regulatory properties of membrane-
bound glycoprotein Ib-Illa with those of the detergent-solu-
bilized receptor. Basal fibrinogen binding to the membranes
possessed many of the properties of fibrinogen binding to
activated platelets; however, less than 10% of glycoprotein
Ib-Illa in the membranes was capable of binding fibrinogen.
Preincubating the membranes with either an activating glyco-
protein lb-Illa antibody or oc-chymotrypsin increased fibrinogen
binding. In contrast, agents that require intracellular mediators,
such as platelet agonists, guanine-nucleotide-binding-protein
activators and purified protein kinase C, did not stimulate
fibrinogen binding to the membranes, suggesting that cytosolic
INTRODUCTION
The membrane glycoproteins (GP) Ilb and Illa form a
heterodimeric complex on the surface of platelets that binds the
adhesive proteins fibrinogen, von Willebrand factor, vitronectin
and fibronectin [1]. The interaction of GP IWb-Illa with either
fibrinogen or von Willebrand factor is required for platelet
aggregation [1]. Fibrinogen binding is bivalent-cation-dependent
and is mediated, at least in part, by RGD (Arg-Gly-Asp)
sequences in the Aa chain of fibrinogen [2] and/or a region in the
C-terminus of the y-chain of fibrinogen [3,4,5]. GP I1b-Illa
belongs to a family of structurally related cell-adhesion receptors,
the integrins, many of which recognize their ligands in an RGD-
dependent manner [6,7]. In addition to recognizing large adhesive
proteins, GP IWb-Illa also binds small synthetic peptides con-
taining either the RGD sequence [8] or the sequence
HHLGGAKQAGDV (H12) derived from the C-terminus of the
y-chain of fibrinogen [3].
Fibrinogen binding to platelets is subject to tight metabolic
control and occurs only after platelets are exposed to an activating
agent, such as thrombin, ADP or thromboxane A2 [9]. The rapid
expression of fibrinogen-binding sites on platelets is the result of
conversion of GP I1b-IIIa from a state that cannot bind
fibrinogen into one that does. In the absence of fibrinogen, the
binding-competent state of GP I1b-Illa disappears, but can be
restored upon exposure to a second agonist [10]. Activation of
GP I1b-Illa parallels other activation-dependent events in
platelets, including alterations in phospholipid metabolism,
factor(s) may be required for activation of the receptor in
platelets. Occupancy of glycoprotein Ilb-Illa in the membranes
with RGD (Arg-Gly-Asp)-containing peptides reversibly exposed
neoantigenic epitopes and fibrinogen-binding sites in the receptor.
These conformational changes required membrane fixation to be
maintained following peptide removal. Similar results were
obtained with purified glycoprotein IlbIlIIa incorporated into
phospholipid vesicles, indicating that the resting state of the
receptor is favoured in these environments. In contrast, when the
conformation of detergent-solubilized glycoprotein Ilb-Illa was
altered by exposure to RGD-containing peptides, the receptor
remained active even after incorporation into phospholipid
vesicles. These results demonstrate that platelet membranes are a
useful model in which to study the regulation of glycoprotein
Ilb-Illa and suggest that the environment surrounding the
receptor may have a profound influence on this process.
mobilization of intracellular calcium, activation of protein
kinases and rearrangement of the cytoskeleton. However, the
precise series of intracellular events that are responsible for the
conversion of GP lI1Ihlla into a functional fibrinogen receptor
is not known.
GP Ib-IIIa exists in at least three distinct and interconvertible
functional states: the resting state that cannot bind adhesive
proteins, the activated state that can bind adhesive proteins and
the ligand-occupied state that is expressed upon the binding of
adhesive proteins. Although the physiological mechanism respon-
sible for converting GP Ib-Ilila from a resting to an activated
state within the platelet remains obscure, the activated state can
be induced independently of intracellular mediators by the
binding of certain GP IIW-/GP Illa-specific monoclonal anti-
bodies (mAb) [11,12,13] or RGD-containing peptides [14].
Moreover, many of the antibodies that recognize the ligand-
occupied state also promote fibrinogen binding to the receptor,
suggesting that the activated and ligand-occupied states are
closely related [15]. The cytoplasmic domains of both GP Ilb and
GP Illa have been implicated in the regulation of the affinity
state of the receptor. A point mutation (Ser752-*Pro) in the
cytoplasmic domain of GP Illa blocks activation of the receptor
in platelets [16], while deletion of the cytoplasmic domain of GP
Ilb renders the protein constitutively active when expressed
recombinantly in cells [17].
While modulation of the fibrinogen binding capacity of both
purified GP Ib-IlIla and GP Il-Illla in intact cells has been
observed, relatively little is known about the regulation of the
Abbreviations used: GP, glycoprotein; GTP[S], guanosine 5'-[y-thio]triphosphate; mAb, monoclonal antibody; PMSF, phenylmethanesulphonyl
fluoride; PGI2, prostacyclin; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; peptides, e.g. YRGDS, are given in the one-letter amino acid
code; LIBS, ligand-induced binding sites.
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fibrinogen-binding properties of GP Ilb-IlIa in purified platelet
membranes. Phillips and Baughan [18] reported that the levels of
fibrinogen binding to platelet membranes are much lower than
those reported for fibrinogen binding to activated platelets. Thus
platelet membranes may provide a model system in which to
study potential mechanisms ofregulation ofGP Ilb-IlIa. Platelet
membranes have been of value in providing information on the
regulation of other activation-dependent processes in platelets,
including hormonal regulation of adenylate cyclase [19] and
phospholipase C [20]. In the present study we characterized the
properties of fibrinogen binding to isolated platelet membranes
and investigated the mechanisms governing the opening and
closing of binding sites on the fibrinogen receptor, GP Ilb-Illa.
EXPERIMENTAL
Materials
a-Chymotrypsin (bovine pancrease) and neuraminidase (from
Vibrio cholera) were purchased from Sigma (St. Louis, MO,
U.S.A.). Synthetic peptides were obtained from the following
sources: GRGDSP and HHLGGAKQAGDV (H12) were from
Biosearch (San Rafael, CA, U.S.A.), and YRGDS was from
Pennisula Laboratories (Belmont, CA, U.S.A.) (peptides are
given in the one-letter amino acid code). Saponin was purchased
from Calbiochem (San Diego, CA, U.S.A) and streptolysin 0
was from the Burroughs Wellcome Co. (Greenville, NC, U.S.A.).
Antibodies
The GP lIla-specific mAb AP3 [21] and the GP Ilb-specific mAb
AP4 were kindly supplied by Dr. Peter Newman and Dr. Thomas
Kunicki of the Blood Center of Southeastern Wisconsin; the GP
Ilb-IlIa complex-specific mAb 10E5, which inhibits platelet
aggregation and fibrinogen binding [22], was generously supplied
by Dr. Barry Coller, State University ofNew York, Stony Brook,
NY, U.S.A.; the GP IlIa-specific mAb 62, which induces the
exposure of fibrinogen-binding sites on GP lIb-Illa [13], the GP
Illa-specific mAb LIBSI, which preferentially recognizes the
ligand-occupied state ofGP lIb-IIIa [15], and the GP Ilb-specific
mAb PMI-1 [23], which recognizes an epitope at the C-terminus
of the heavy chain of GP Ilb, were provided by Dr. Mark
Ginsberg, the Scripps Research Institute, La Jolla, CA, U.S.A.;
the activation-dependent anti-(GP Ilb-IIIa) mAb PAC-1 [24]
was generously given by Dr. S. Shattil; rabbit polyclonal anti-
bodies to GP Ilb-IIIa were obtained from Dr. David Phillips,
COR Therapeutics.
Fibrinogen purification
Fibrinogen was purified from fresh-frozen plasma by the glycine
precipitation method of Kazal et al. [25] with an additional
gelatin-Sepharose chromatography step to remove contami-
nating fibronectin. The concentration of fibrinogen was deter-
mined spectrophotometrically (A280), assuming an absorption
coefficient (Am8%) of 15.1 and a molecular mass of 340 kDa.
Fibrinogen was centrifuged (11600 g) for 5 min before use.
lodinatlon of YRGDS and proteins
Radioiodinations were catalysed by chloramine-T (0.05 mg/ml)
and stopped with sodium metabisulphite (0.05 mg/ml). Un-
incorporated Na'251 was separated from radiolabelled YRGDS
by gel filtration on Sephadex G-10 (Pharmacia LKB
Biotechnology, Piscataway, NJ, U.S.A.) and from radioiodinated
proteins by gel filtration on PD-10 columns (Pharmacia). The
specific activity was - 5 x 1016 and -1 x 1018 c.p.m./mol for
1251-labelled YRGDS and 125I-labelled proteins respectively.
Platelet isolation and functional analysis
Platelet-rich plasma from acid-citrate/dextrose-anticoagulated
human blood was centrifuged at 800 g for 20 min, and the
resulting platelet pellet was resuspended in Tyrode's solution
(5.5 mM glucose/138 mM NaCl/12 mM NaHCO3/0.36 mM
NaH2PO4, and 10 mM Hepes, pH 7.4) containing 0.35 % BSA
and 150 nM prostacyclin (PGI2). Platelets were washed twice by
centrifugation at 800 g for 15 min. Between spins, the platelets
were incubated at 37 °C for a minimum of 15 min. Platelets were
resuspended at 3 x 108/ml in Tyrode's solution containing 2 mM
CaCl2, 1 mM MgCl2 and 0.35 % BSA and tested for their ability
to aggregate to one of the following: 0.1 unit/ml thrombin;
10 ,uM phorbol 12-myristate 13-acetate (PMA); or 0.6 ,uM
U46619 (a thromboxane A2 mimetic).
Fibrinogen-binding assays were performed in a total volume of
200,a1 containing Tyrode's solution with 2 mM CaCl2, 1 mM
MgCl2 and 0.35 % BSA. Binding was initiated by the addition of
a platelet agonist and 1251-fibrinogen. Bound fibrinogen was
separated from free fibrinogen by centrifuging (13 500 g for
2 min) 50 ,1 of the reaction mixture through 400 ,u of20% (w/v)
sucrose, aspirating the liquid, and quantifying the amount of
radioactivity associated with the platelet pellet. In some instances
suspensions of washed platelets were incubated with
chymotrypsin for 20 min at room temperature or mAb 62 for
30 min at 37 °C before assessing the ability of the platelets to
aggregate or to bind fibrinogen. Chymotrypsin was inactivated
by the addition of 200-fold molar excess of phenylmethane-
sulphonyl fluoride (PMSF) to enzyme.
Platelet membrane preparation
Outdated platelets (American Red Cross) were isolated from
platelet-rich plasma by centrifugation (700 g, 20 min) and washed
twice in 120 mM NaCl/13 mM trisodium citrate/30 mM
dextrose, pH 7.0. Washed platelets were resuspended in buffer A
(150 mM NaCl/l0 mM Tris, pH 7.4) and placed in the pressure
chamber of a Parr cell disruption bomb (Parr Instrument Co.,
Moline, IL, U.S.A.). The chamber was filled with nitrogen to a
pressure of 8280 kPa (1200 lbf/in2) and maintained at 22 °C for
30 min. The contents were discharged into the same buffer with
final concentrations of 0.1mM PMSF, 10/g/ml aprotonin
and 0.1 mg/ml leupeptin. The resultant suspension was
centrifuged at 100000 g for 30 min at 4°C. The pellet was
resuspended in buffer A, layered over 27% sucrose in buffer A
and centrifuged at 27000 rev./min for 3 h in an SW 28 Beckman
rotor. The membranes were retrieved from the interface of the
sucrose solution, resuspended in buffer A with 1 mM CaCl2, and
centrifuged for 1 h at 100000 g at 4 °C.
Enzyme assays
For sialic acid analysis, platelet membranes were treated with
0.1 unit/ml neuraminidase for 120 min at 37 °C with or without
prior solubilization in 0.05 % Triton X-100. Released sialic acid
was measured by the thiobarbituric acid assay described by
Warren [261.
Phosphodiesterase activity was measured by hydrolysis of
0.1 mM bis-(p-nitrophenyl) phosphate in 30 mM MgCl2/30 mM
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Tris, pH 8.8. The reaction was initiated by the addition of
membranes that had been preincubated for 1 min with or without
0.1% Triton X-100. The A420 of the solution was read after the
addition of membranes and again after a 30 min incubation at
37 'C. The difference between the two readings is a measure of
phosphodiesterase activity in the membranes [27].
Ligand binding to purffmed platelet membranes
Platelet membranes were incubated in a total volume of 200 ,u
containing 100 mM NaCl, 2 mM CaCI2, 1 mM MgCl2, 0.5 %
BSA, 50 mM Tris, pH 7.4, and 125I-labelled ligand for 1 h at
room temperature. The reactions were terminated by filtering 50
,1 aliquots through polycarbonate filters (0.2,um pore size;
Nuclepore, Cambridge, MA, U.S.A.). The filters were washed
three times with 1 ml of ice-cold buffer (100 mM NaCl/ 1 mM
CaCl2/0.02 % NaN3/50 mM Tris, pH 7.4), and the radioactivity
associated with the filters was quantified. Non-specific binding
was defined as the amount of 1251-ligand bound in the presence
of 3 ,uM non-radioactive ligand. In some instances, equilibrium
dialysis was also performed as previously described [45] to
measure the binding of 125I-peptide to the membranes.
Chymotrypsin treatment of platelet membranes
Platelet membranes were incubated in 50 mM Tris (pH 7.4)/
100 mM NaCl/ 1 mM CaCl2 with various concentrations of
chymotrypsin for 30-60 min at room temperature. The reactions
were terminated by the addition of 200-fold molar excess of
PMSF. Aliquots of the chymotrypsin-treated membranes were
incubated with 1251-fibrinogen in the binding assay or solubilized
in SDS sample buffer for gel electrophoresis.
Protein kinase C (PKC) purification and membrane protein
phosphorylation
Rat brain PKC was purified by sequential DEAE-cellulose,
threonine-Sepharose and phenyl-Sepharose chromatography as
described by Kitano et al. [28] PKC activity was assayed in
20 mM Tris (pH 7.4)/5 mM magnesium acetate/10,M [y-
32P]ATP/0. 1 mM CaCl2/40 ,ug/ml phosphatidylserine/2 ,tg/ml
diolein (dioleoylglycerol). The specific activity of the purified
enzyme was 0.7 Iumol of phosphate transferred/min per mg of
protein using histone HI (200 ,ug/ml) as the substrate.
Membrane phosphorylation reactions were conducted in
10 mM Tris (pH 7.4)/5 mM MgCl2/l mM CaCl2/100 uM ATP
for 60 min at 37 'C with or without the addition of purified 10 ,ul
PKC (0.1 mg/ml). In some cases the membrane-permeabilizing
agents saponin (1-100 /ug/ml) or streptolysin 0 (1 unit/ml) were
included in the binding reaction. Previous studies indicated that
30 ,tg/ml saponin or 1 unit/ml streptolysin 0 were sufficient to
permeabilize intact platelets, as determined by measuring platelet
aggregation in response to the membrane-impermeable reagent
guanosine 5'-[y-thio]triphosphate (GTP[S]). The phosphoryl-
ation of platelet membrane proteins was monitored by including
[y-32P]ATP in the reaction, solubilizing the proteins in SDS
sample buffer and subjecting them to SDS/PAGE. 32P-labelled
bands were revealed by autoradiography.
GRGDSP Incubations and membrane fixations
Membranes were incubated without or with GRGDSP for
15 min at room temperature, diluted in Buffer A with 1 mM
CaCl2, centrifuged at 13 000 g for 60 min and initially re-
suspended in the same buffer. Ligand-binding studies were per-
formed with buffers as described for ligand binding to platelet
membranes. For fixation studies, membranes incubated with or
without GRGDSP were diluted with an equal volume of 1%
paraformaldehyde in 0.075 M sodium phosphate (pH 7.4)/0.075
M NaCl, incubated for an additional 60 min at room temperature
and neutralized with an equal volume of 500 mM NH4C1 in
10 mM sodium phosphate/150 mM NaCl. The fixed membranes
were washed, resuspended as described above, and ligand-binding
studies were performed as described above.
GP lib-Illa purfflcation and incorporation into phospholipid
vesicles
GP Ilb-Illa was purified from outdated platelets that were
lysed in 50 mM octyl glucoside/lO mM Hepes (pH 7.4)/150 mM
NaCl/2 mM CaCl2/1 mM MgCl2. After centrifugation at
30000 g for 15 min, the platelet lysate was applied to a con-
canavalin A affinity column and the bound glycoproteins were
eluted with 500 mM oc-methylmannose in the above buffer [29].
The fractions containing the peak of GP Ilb-Illa were pooled,
applied to sequential heparin-Sepharose and gelatin-Sepharose
columns and concentrated approx. 5-fold to 1 mg/ml by ultra-
filtration. GP Ilb-Illa, judged to be > 85 % pure by scanning
densitometry of SDS/polyacrylamide gels, was incorporated
into 70% phosphatidylserine/30% phosphatidylcholine phos-
pholipid vesicles [1:2.9 (w/w) protein/lipid ratio] by detergent
dialysis as described in [30]. Ligand binding to the vesicles was
performed as described for ligand binding to platelet membranes.
SDS/PAGE and Western blotting
Proteins were solubilized in 2% SDS/20% glycerol/O. 125 M
Tris, pH 6.8, in the presence (reducing conditions) or absence
(non-reducing conditions) of 2% (v/v) ,-mercaptoethanol and
separated on SDS/7.5% or 5-20% polyacrylamide gels [31].
The gels were stained with Coomassie Brilliant Blue R250 or
equilibrated in transfer buffer [5OmM Tris/(pH9.2)/55mM
glycine/1 mM SDS/20% methanol] for Western blotting.
Proteins were transferred to nitrocellulose with a Gelman semi-
dry graphite-electrode apparatus. The nitrocellulose was
incubated with primary antibody in 100 mM Tris/0.9 %
NaCl/O. 1 % Tween 20 for 30 min at room temperature, and the
bound Abs were detected with the Vectastain ABC horseradish
peroxidase detection system (Vector Laboratories, Burlingame,
CA, U.S.A.).
RESULTS AND DISCUSSION
Properties of purified platelet membranes
Isolated platelet membranes were prepared by nitrogen cavitation
of washed platelets followed by sucrose-density sedimentation.
Electron micrographs indicate that this procedure yields relatively
pure intact platelet membranes (results not shown). The ac-
cessibility of the outer surface of the membranes was assessed by
treating the membranes with neuraminidase in the presence or
absence of 0.05 % Triton X-100. Neuramidase cleaves sialic acid
residues, which are located exclusively on the extracellular
portions of membrane proteins. In intact and solubilized
membranes, neuraminidase hydrolysed similar amounts of sialic
acid (53.4 and 53.9 nmol/mg of membrane protein respectively),
demonstrating that the extracellular face of the membranes is
exposed. The accessibility of the inner surface of the membranes
was evaluated by measuring phosphodiesterase activity in the
presence and absence of 0.1 0% Triton X-100. Phosphodiesterase
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Figure 1 Protein content of purffled platelet membranes
Platelet membranes (25 ,ug; lane 1) and purified GP llb-lIla (2.5 1ug; lane 2) were solubilized
in 2% SDS, reduced with 2% fi-mercaptoethanol and electrophoresed through a 5-20%-
polyacrylamide gel. The gel was stained with Coomassie Brilliant Blue; the positions of the
molecular-mass markers are indicated.
activity was similar with or without membrane solubilization
(0.62 units/mg of protein versus 0.78 unit/mg of protein re-
spectively), indicating that the inner surface of the membranes
is accessible to small molecules such as bis-(p-nitrophenyl)
phosphate.
The protein content of the membranes is shown in the
Coomassie Blue-stained SDS/polyacrylamide gel in Figure 1.
Two heavily stained proteins in the membranes co-migrate with
purified GP Ilb and GP Illa and react with anti-(GP Ilb-Illa)
antibodies on Western blots. To estimate the amount of
complexed GP Ilb-Illa in these membranes, binding of the
GP Ilb-Illa complex-specific mAb lOE5 was quantified;
5.84 x 10-10 mol of 1251-lOE5 were bound per mg of membrane
protein, which represents approx. 15% of total membrane
protein.
Fibrinogen-binding properties of platelet membranes
The amount of 1251-fibrinogen binding to the membranes
increased linearly as increasing concentrations of membrane
protein (5-50 ,ug) were included in the assay. Fibrinogen binding
(10 nM) to the membranes was time-dependent and reached
steady state within approx. 30 min at room temperature (results
not shown). Excess non-radioactive fibrinogen competed for
radiolabelled fibrinogen binding, indicating that fibrinogen bind-
ing to the membranes is saturable. Maximal inhibition was
observed when a 100-fold excess of non-radioactive fibrinogen
was included in the binding reaction (IC50 100 nM; Figure
2a).
Competition binding studies with three different agents that
interact with GP Ilb-IIIa suggest that fibrinogen is binding to
GP Ilb-Illa in the membranes. First, the GP lIb-Illa-specific
mAb IOE5, which blocks fibrinogen binding to whole platelets
[22], inhibited fibrinogen binding to the membranes (Figure 2b).
Moreover, the synthetic peptides GRGDSP (Figure 2c) and H12
(Figure 2d) competed for fibrinogen binding to the membranes,
while the control peptide GRGESP had no effect. The
concentrations of GRGDSP and H12 required for 50% in-
hibition of 1251-fibrinogen binding were 50 and 20 ,uM respect-











5 10 100 1000 0 10 100
[RGDS] (pM) [H12 peptidel (pM)
1000
Figure 2 Inhibition of Ill-fibrlnogen binding to platelet membranes
Platelet membranes (25 ,ug) were incubated for 60 min with 1251-fibrinogen in the presence of
various concentrations of non-radioactive fibrinogen (a), the GP llb-lila specific mAb lOE5 (b),
the synthetic peptide GRGDSP (c) or the synthetic H12 peptide (d) corresponding to the
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Figure 3 Saturaton isotherm and Scatchard analysis of 1251-fibrinogen
binding to platelet membranes
(a) Platelet membranes (25 ,tg) were incubated for 60 min at room temperature with increasing
concentrations of 1251-fibrinogen (10-400 nM). Non-specific binding was defined with 3 ,uM
non-radioactive fibrinogen, with the amount of saturable binding ranging from 60 to 80% of total
binding. (b) Analysis of the same data by the method of Scatchard [53]. Data are plotted as
pmol of radioligand bound/mg (abscissa) versus bound ligand divided by free-ligand
concentration (ordinate). The data are representative of results obtained for ten different
membrane preparations in which the affinity constant (Kd) for fibrinogen binding ranged from
15 to 50 nM and the maximal binding capacity (Bma,,) for fibrinogen was less than 60 pmol/mg
of protein.
1251-fibrinogen binding to agonist-stimulated platelets, with
reported IC50 values of 30-50 ,uM for RGD peptides [32,33] and
15-75,M for H12 [3,34,35]. Thus fibrinogen binding to the
membranes displays many of the properties offibrinogen binding
to whole platelets and to purified GP Ilb-Illa.
Equilibrium binding studies demonstrated that 1251-fibrinogen
binding is saturable. Scatchard transformation of the data
revealed that fibrinogen binds with high affinity, apparently to a
single class of sites (Figure 3). In ten different membrane
preparations the dissociation constant (Kd) for fibrinogen binding
ranged from 15 to 50 nM, compared with reported values of
50-500 nM for fibrinogen binding to whole platelets [1] and
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Figure 4 Chymotrypsin-induced flbrinogen binding to membranes
Membranes were preincubated with various concentrations of chymotrypsin (0-50 ,ug/ml) for
60 min at room temperature and the reaction was terminated by the addition of 1 mM PMSF.
1251-fibrinogen binding (30 nM) to the membranes was assayed as described in the
Experimental section. Results are means+ S.E.M. for triplicate samples.
maximal binding capacity (Bmax ) of the membranes was
< 60 pmol offibrinogen bound/mg of protein. A similar number
of binding sites were observed in membranes prepared from
platelets disrupted by sonication. Thus the density of fibrinogen
binding sites is only a fraction of the total GP lIb-Illa
(- 600 pmol/mg of protein) in the membranes, indicating that
only a small proportion (< 10%) of the receptors are
functional. In this manner the fibrinogen-binding properties of
the membranes are similar to those of resting platelets in that
substantial amounts of GP Ilb-Illa are present but unable to
bind fibrinogen.
Exposure of fibrinogen-binding sites in membranes by the serine
protelnase chymotrypsin
The low levels of fibrinogen binding to the membranes could be
explained if the membrane isolation procedure rendered GP
Ilb-IlIa non-functional. We therefore sought to determine
whether the fibrinogen-binding capacity of GP IIb-Illa in the
membranes could be increased in a manner independent of
intracellular mediators. Chymotrypsin treatment of intact
platelets in the absence of intracellular metabolic events exposes
cryptic fibrinogen-binding sites on GP Ilb-Illa by either
proteolysis of GP Ilb-Illa or an accessory molecule [36,37]. We
observed spontaneous aggregation of platelets in the presence of
exogenous fibrinogen after exposure of platelets to 30-150 ,ug/ml
chymotrypsin for 20 min at room temperature, which correlated
with an increase in l25l-fibrinogen binding to chymotrypsin-
treated platelets (results not shown).
We next examined the ability of chymotrypsin to increase the
fibrinogen binding properties of membranes. When membranes
were incubated with increasing concentrations of chymotrypsin
and then assayed for fibrinogen binding, a 3-fold increase in the
amount of 1251-fibrinogen bound was observed in membranes pre-
treated with 0.05-0.5 ,ug/ml chymotrypsin (Figure 4). Pretreat-
ment with higher concentrations of chymotrypsin (1-100 jig/ml)
dose-dependently decreased fibrinogen binding (Figure 4).
Western-blot analysis of chymotrypsin-treated membranes
indicated that the chymotrypsin-induced increase in fibrinogen
binding did not correlate with digestion of either GP Ilb or GP
Illa. The mobility of non-reduced (Figure 5a, lanes 1-5) and
reduced (Figure 5b, lanes 1-4) GP Ilb was unaltered following
the exposure of membranes to 0.05-1 ,g/ml chymotrypsin,
conditions under which an increase in fibrinogen binding was
observed (Figure 4). Immunoblot analysis with the GP Ilb-
specific mAbs AP4 and PMI-l (Figure 5c, lanes 4-9) revealed
that GP Ilb was converted into a lower-molecular-mass form
(- 80 kDa) in membranes exposed to 10 ,ug/ml chymotrypsin.
At concentrations of chymotrypsin required for exposure of
fibrinogen-binding sites in the membranes, we did not observe
the limited proteolysis of GP Ilb that results in the release of the
PMI-l epitope and reportedly coincides with chymotrypsin-
induced fibrinogen binding to intact platelets [38], even when we
separated the proteins on 5 %-polyacrylamide gels (results not
shown). Differences in assay systems may account for our
inability to detect this reaction.
As in intact platelets, GP Illa in membranes was more sensitive
to proteolysis by chymotrypsin. Limited cleavage of the
proteolytically sensitive disulphide loop in GP Illa to generate a
1lOkDa proteolytic product was observed at 0.1ltg/ml
chymotrypsin (Figure Sa, lanes 3) and was more prominent at
higher doses (1-10 jug/ml) of chymotrypsin (Figure 5a, lanes
5-7; Figure 5c, lanes 1-3). High doses of chymotrypsin (>
10 ,ug/ml) produced 68 and 51 kDa forms of GP Illa (Figure 5a,
lane 8; Figure 5b, lanes 6-8; Figure 5c, lane 3). The identity of the
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Figure 5 Western-blot analysis of GP lib-ilia in chymotrypsin-treated membranes
Membranes (25 ,ug) were incubated with the indicated concentration of chymotrypsin (0.05-100 ,ug/ml) for 60 min at room temperature, at which time the reaction was terminated by the addition
of PMSF. The proteins were separated on a SDS/7.5%-polyacrylamide gel run under non-reducing (a and c) or reducing conditions (b). GP Ilb and GP Ilia were revealed by Western blotting
with anti-(GP llb-lila) polyclonal Abs (a and b), with the GP Ilia-specific mAb AP3 (c, lanes 1-3), with the GP (lb-specific mAb AP4 (c, lanes 4-6) or with the GP (lb-specific mAb PMI-1 (c,
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110 kDa and the 68 kDa proteins was confirmed by immuno-
reactivity with the GP lIla-specific mAb AP3 (Figure 5c, lanes
1-3). Although initial reports correlated the acquisition of
fibrinogen-binding properties of chymotrypsin-treated platelets
with the generation of a 68 kDa fragment of GP lIla [39], our
results indicate that the appearance of this fragment occurs at
higher concentrations of chymotrypsin than are needed to
stimulate fibrinogen binding. Indeed, as reported by others
investigating chymotrypsin-treated platelets [40], we find that the
presence of the 68 kDa fragment correlates with a decrease in
fibrinogen binding to the membranes. The 68 kDa fragment is
generated by proteolysis of a large disulphide-bonded loop in GP
IlIa that contains the putative RGD-binding site [41]. Loss ofthis
region of GP Illa may account for the decline in fibrinogen
binding to membranes.
Our inability to correlate digestion of either GP Ilb or GP Illa
with the exposure of additional fibrinogen-binding sites in
membranes could arise if our Western-blot analysis was not
sensitive enough to detect either minor alterations in the structure
of the proteins or alterations in a subpopulation of the receptors.
Alternatively, chymotrypsin may expose fibrinogen-binding sites
in membranes by cleaving a molecule associated with GP
Ilb-Illa. This hypothesis is supported by the finding that,
following chymotrypsin digestion of intact platelets, the
proteolytic products of GP Ilb-Illa are unable to bind either
immobilized fibrinogen [42] or RGD peptides [41].
Induction of fibrinogen binding to membranes by a GP lila-
specmc mAb
Several mAbs directed against GP Ilb and/or GP Illa induce
fibrinogen binding to GP Ilb-Illa, apparently by shifting the
receptor from a low- to a high-affinity state [11-13]. One such
mAb, 62 [13], was used as a second tool to stimulate fibrinogen
binding to membranes. Incubation of intact platelets with mAb
62 (3-6 ,uM) resulted in aggregation upon addition of fibrinogen,
without the need for a platelet agonist (results not shown). When
preincubated with membranes, mAb 62 dose-dependently in-
creased fibrinogen binding to GP Ilb-Illa (Figure 6). At the
highest concentration tested (1.8 uM), mAb 62 promoted a 5-
fold increase in fibrinogen-binding levels. The activating mAb 62
also increased the number of binding sites for PAC-1, a GP
Ilb-IlIa-specific mAb that recognizes an epitope exposed only
in the activated form of the receptor. Maximally effective
concentrations of mAb 62 (10 1M) stoichiometrically exposed
PAC-1-binding sites in GP Ilb-Illa in the membranes
(Bmax > 650 pmol/mg of protein; results not shown). Thus mAb
62 induces a ligand-binding competent form of GP Ilb-Illa in
membranes, presumably by directly affecting the conformation
of the receptor.
Effects of platelet activators on flbrinogen binding to membranes
Having established that the fibrinogen-binding activity of GP
Ilb-Illa in platelet membranes could be increased under con-
ditions that by-pass the platelet-activation process, we next
examined the effects of platelet activators on the fibrinogen-
binding capacity of membranes. Fibrinogen binding to platelets
is stimulated by the platelet agonists thrombin and U46619 (a
thromboxane A2 analogue), presumably by receptor-mediated
activation of a guanine-nucleotide-sensitive binding protein (G-
protein) and a subsequent cascade of intracellular events in-
volving PKC. In contrast with their effects on intact platelets, the
platelet agonists ADP, thrombin and U46619 did not stimulate
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Figure 6 Induction of flbrinogen binding by a GP llb-Illa-activating mAb
Binding of 1251-fibrinogen (30 nM) to platelet membranes was measured in the absence or
presence of various concentrations of activating mAb 62. Binding reactions were allowed to
proceed for 60 min at room temperature as described in the Experimental section. Results are
means+S.E.M. for triplicate samples.
Table 1 Effects of platelet activators on fibrinogen binding to membranes
Platelet membranes were incubated with the indicated platelet activators and 1251-fibrinogen for
1 h at room temperature. The amount of fibrinogen bound was measured as described in the
Experimental section. The combined results from two separate experiments performed in
triplicate are reported.
Fibrinogen bound






U46619 (0.6 MM) + GTP[S] (50 MM)
PMA (5MM)
ATP (100MM)












or in combination with the G-protein activators NaF, GTP or
GTP [S] (Table 1). Enzymic analysis revealed that both the inner
and outer surfaces of the membranes were accessible to small
molecules (see above), eliminating one explanation for these
results. In platelet membrane preparations similar to ours,
receptor- and G-protein-mediated regulation of adenyl cyclase
has been observed [19], indicating that at least part of the
stimulus-coupling machinery is intact in this system. Our findings
suggest that agonist-receptor occupancy cannot directly regulate
GP Ilb-IIla activity in the membranes.
In agonist-stimulated platelets, the exposure of fibrinogen-
binding sites on GP Ilb-IlIa correlates closely with PKC activity
[10]. Although direct phosphorylation of GP lIb-Illa does not
appear to regulate the state of the receptor [43], PKC may
control fibrinogen binding by altering the phosphorylation of an
unidentified regulatory protein. We examined the effects of
membrane protein phosphorylation on the binding capacity of
GP Ilb-Illa. Platelet membranes possess endogenous protein
kinase activity, as detected by the incorporation of[32Plphosphate
into specific membrane proteins (Figure 7, lane 1). The addition
of PKC to membranes resulted in [32P]phosphate incorporation
into at least one additional protein with a molecular mass of
approx. 70 kDa (Figure 7, lane 2). Under conditions where
specific protein phosphorylation was observed, fibrinogen bind-
ing to the membranes was not promoted by treatment of the
Regulation of the affinity state of glycoprotein Ilb-lila in platelet membranes
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Figure 7 Platelet membrane phosphorylation
Membranes were incubated for 30 min at 37 'C with 10 ,sM [y-32P]ATP (lane 1) or 10 1sM
[~-32P]ATP and purified PKC (lane 2). Lane 3, purified PKC was incubated with 10 JM [y-
P]ATP in the absence of platelet membranes. The arrow points to a 70 kDa protein
specifically phosphorylated by PKC. The positions of molecular-mass markers are indicated.
membranes with phorbol esters, ATP or purified PKC (Table 1).
To rule out the possibility that substrates in the membranes were
inaccessible to PKC, the experiments were repeated in the
presence of the membrane-permeabilizing agents saponin and
streptolysin 0. The permeabilizing agents did not alter the
phosphorylation patterns or basal fibrinogen binding to the
membranes; moreover, they did not result in higher fibrinogen
binding with the addition of PKC (results not shown). Taken
together, these results suggest that the affinity state of GP
Ilb-Illa may be controlled by phosphorylation/dephosphoryl-
ation of(a) cytoplasmic component(s) that is (are) lost during the
membrane isolation procedure.
YRGDS binding to membranes
RGD-containing peptides reportedly interact with resting
platelets [44] and purified GP lIb-Illa [45]. The ability of
GRGDSP to compete for fibrinogen binding to membranes
(Figure 2c) suggested that RGD-containing peptides could
potentially interact with GP Ilb-IIIa in the membranes. Thus the
binding of 11261-YRGDS to the membranes was characterized.
The binding of 1151-YRGDS to the membranes increased over
time and approached steady state within 1 h at room temperature
and within 6 h at 4 'C. The binding was specific and saturable in
that excess non-radioactive YRGDS, GRGDSP or bivalent-
cation chelation inhibited 1251I-YRDGS binding (results not
shown). Determination of the equilibrium binding constants for
1251-YRGDS binding to the membranes revealed that the affinity
constant (Kd) is approx. 150 #M (Figure 8). Thus the affinity of
membrane for YRGDS, as determined by equilibrium-binding
analysis, is in the range of the affinity for GRDGSP, as
determined by inhibition of fibrinogen binding (IC50 approx.
50 1M). The maximal binding capacity (Bmax:) of membranes for
YRGDS was 700 pmol/mg of protein, which corresponds to the
total GP Ilb-Illa content of the membranes (600 pmol/mg of
protein). Thus, as in resting platelets, GP Ilb-IIIa in the
membranes appears to be capable of interacting stoichio-
merialywth sho^rt peptn;ide sequeances butf not witht ;ilntac














Figure 8 Analysis of 121-YRGDS binding to membranes
Membranes (25 #tg) were incubated with 1251-YRGDS and various concentrations of
nonradioactive YRGDS for 60 min at room temperature. (a) The data were plotted as total
YRGDS added (abscissa) versus bound YRGDS (ordinate). (b) Data were replotted according
to the method of Scatchard [53] and are plotted as pmol of YRGDS bound/mg (abscissa) versus
bound ligand divided by free ligand (ordinate). The data are the combined results from three
separate experiments. The affinity constant (Kd) for YRGDS binding to membranes was
200 MM, and the maximal binding capacity (Bmax) was 700 pmol/mg of protein.
Control membranes Washed membranes Fixed membranes
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Figure 9 Exposure of mAb LIBS 1-binding sites in membranes by GRGDSP
The ability of GRGDSP to expose LIBS in GP lb-Illa in membranes was assessed by measuring
the binding of 125l-mAb LIBS 1 (80 nM; 3) to membranes that were pretreated with buffer
('CTL') or 1 mM GRGDSP for 15 min at room temperature (a), to membranes that were
pretreated with buffer or GRGDSP as above and washed to remove the peptide as described
in the Experimental section (b), and to membranes that were pretreated with buffer or peptide,
fixed in 0.5% paraformaldehyde for 1 h and then washed to remove peptide (c). 1251-mAb 1OE5
binding (200 nM; *) was performed under each of the three conditions to measure the total
amount of exposed GP llb-lila.
YNRGDS (20 ,uM), platelet membranes bound a larger quantity
of peptide in the presence of activating mAb 62 (results not
shown), suggesting that changes in the state of GP Ib-IlIa may
affect the receptor's affinity for peptides.
Effects of RGD peptdde occupancy on the conformational state of
GP lib-Ilia
Previous reports indicate that occupancy of GP Ilb-Illa with
RGD-containing peptides alters the conformation ofthe receptor
[46] and exposes neoantigenic sites termed 'ligand-induced bind-
ing sites' (LIBS) [47,48]. In membranes, RGD-containing
peptides similarly altered the conformation of GP IIb-IIIa to
expose LIBS that were recognized by the conformationally
sensitive anti-(GP IIIa) mAb LIBS 1 (Figure 9a). The con-
formational changes in GP IIb-IIIa induced by the peptide were
reversed upon removal of the peptide (Figure 9b), but could be
maintained if the membranes were incubated with GRGDSP and
subsequently fixed with paraformaldehyde (Figure 9c).
Du and co-workers [14] demonstrated that the conformation
of ligand-occupied GP Ilb-IIla appears to be similar to the
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Figure 10 151-fibrinogen (Fg) and 1I51-mAb 10E5 (10E5) binding to
membranes pretreated with GRGDSP
(a) Membranes (35,ug) were pretreated without ('CTL') or with the peptide GRGDSP (1 mM)
for 15 min at room temperature. The reaction was terminated by dilution and centrifugation as
described in the Experimental section. Binding of 1251-fibrinogen (200 nM; U) or 1251-mAb
lOE5 (200 nM; *) to the resuspended membranes was quantified. (b) Membranes were
incubated without or with 1 mM GRGDSP for 15 min as above, fixed for 60 min in 0.5%
paraformaldehyde, then diluted and centrifuged to remove the peptide. The resuspended
membranes were incubated with 1251-fibrinogen (200 nM; ) or 1251-mAb 1 OE5 (200 nM; *).
mAb 10E5 binding is a measure of the total amount of GP Ilb-lila available for ligand binding.
detergent-solubilized GP Ilb-IIIa to RGD peptides irreversibly
converts the receptor into a fibrinogen-binding competent form.
In contrast, in intact platelets, both RGD-induced [47,49] and
agonist-induced [10] changes in the conformation ofGP Ilb-Illa
are reversible. The active form of the receptor on platelets can be
preserved by paraformaldehyde fixation of the cells [14,50].
To determine whether the conformational changes associated
with peptide occupancy of GP Ilb-Illa in membranes altered the
receptor's ability to recognize fibrinogen, membranes were
pretreated with 1 mM GRGDSP and assayed for fibrinogen
binding. Membranes exposed to GRGDSP failed to bind sub-
stantial amounts of fibrinogen following removal of the peptide
(Figure lOa). Binding and subsequent removal of the peptide was
monitored by following 1251-YRGDS binding (85 % of bound
peptide removed). Thus RGD peptides appear to interact with
Membranes











GP Ilb-Illa, but any conformational changes induced in the
receptor are reversed upon removal of the peptide. However,
membranes that were incubated withGRGDSP and subsequently
fixed with paraformaldehyde displayed levels of fibrinogen bind-
ing equal to the total amount of GP IIb-Illa in the membranes
(Figure lOb). Fixation alone, in the absence ofRGD peptide, did
not promote fibrinogen binding (Figure lOb). When the
conformational state of GP Ilb-Illa in the membranes was
assessed with the activation-dependent mAb PAC-1, the results
mirrored those obtained for fibrinogen binding to the membranes.
Purified platelet membranes bound low levels of mAb PAC-1.
The binding was inhibited by co-incubation with GRGDSP and
enhanced by the 'activating' mAb 62 (Figure lla, 'CTL'). The
inhibitory effect of GRGDSP on PAC-l binding was lost upon
removal of the peptide (Figure lla, 'Washed'). However,
membranes that were pretreated with GRGDSP and fixed with
paraformaldehyde bound high levels ofPAC-1 following removal
of the peptide (Figure lla, 'Fixed'). Fixation alone slightly
elevated PAC-1 binding. Thus synthetic peptides alter the con-
formation of GP Ilb-IIIa in membranes such that the receptor
assumes a reversible PAC-1- and fibrinogen-binding-competent
form that can be maintained by membrane fixation.
The reversibility of RGD-induced changes in GP Ilb-Illa in
intact platelets and isolated membranes but not in detergent-
solubilized GP Ilb-Illa suggests that a lipid environment may
influence the affinity state of GP Ilb-Illa. To investigate
further the role of lipids on the conformation ofGP Ilb-Illa, we
examined the effect of GRGDSP on purified GP Ilb-Illa
incorporated into phospholipid vesicles, where it has been
previously reported that most of the GP lIb-Illa does not bind
fibrinogen [30]. When GP Ilb-Illa was incorporated into
phospholipid vesicles, the effects of peptide on the conformation
of receptor were also reversible and required paraformaldehyde
fixation to be maintained (Figure 1 Ib). As was the case for PAC-
1 binding to membranes, basal PAC-1 binding to the vesicles was
low and was enhanced by mAb 62 (Figure 1 Ib, 'CTL'). Vesicles
exposed to GRGDSP and washed to remove the peptide failed
to bind high levels of PAC-l, unless the vesicles were fixed prior
to the removal ofthe peptide (Figure 1 Ib, 'Washed' and 'Fixed').
The exposure of LIBS 1-binding sites in purified GP Ilb-Illa
incorporated into phospholipid vesicles was similarly reversed in
Phospholipid vesicles
(b) E] Buffer M GRGDSP M mAb 62
CTL Washed Fixed
Figure 11 Induction of 1251-mAb PAC-1 binding to purffled platelet membranes and GP lib-Ilia Incorporated into phospholipid vesicles
Platelet membranes (a) and phospholipid vesicles containing GP Ilb-lila (b) were incubated with buffer (O) or 1 mM GRGDSP (3) for 15 min at room temperature. The effect of this treatment
on the activation state of GP Ilb-lila was assessed by measuring the binding of 1251-mAb PAC-1 (80 nM) without peptide removal ('CTL'), after removal of the peptide ('Washed') or following



















Figure 12 Peptide-induced changes in detergent-solubilized GP lib-liia
are retained after incorporation of the complex into phospholipid vesicles
GP lb-lila in octyl glucoside buffer was incubated with buffer or 1 mM GRGDSP for 30 min
at room temperature before the proteins were incorporated into phospholipid vesicles. The
binding of 'l251-mAb 1OE5 (0) or 1251-mAb PAC-1 (1) to phospholipid vesicles was measured.
Results are shown as the amount of 1251-ligand specifically bound. Non-specific binding was
defined as the amount of ligand bound to phospholipid vesicles lacking GP lb-llila.
the absence of peptide (results not shown). Thus our results
indicate that, while we can induce a fibrinogen binding-competent
form of GP Ilb-Illa in platelet membranes or phospholipid
vesicles, the activated state of the receptor reverts to the resting
state in the absence of a perturbing agent (e.g. membrane protein
proteolysis, an activating mAb or paraformaldehyde fixation).
Since the exposure of fibrinogen-binding sites on GP Ilb-Illa
in detergent solution by peptides has been reported to occur
irreversibly [14,49], we sought to determine whether such changes
in GP Ilb-Illa could be maintained following the incorporation
of the protein into phospholipid vesicles. In these experiments, GP
Ilb-Illa in octyl glucoside-containing buffer was incubated with
GRGDSP before incorporation into phospholipid vesicles. Under
these conditions, an increase in mAb PAC-1 binding was observed
to phospholipid vesicles containing GP Ilb-Illa that had been
pre-exposed to peptide (Figure 12). These results suggest that
the effects of GRGDSP on the conformation of GP Ilb-Illa
depends on the environment surrounding the receptor at the time
of peptide treatment.
Regulation of the affinity state of GP Ib-Illa in intact
platelets may require the concerted actions of elements that
promote fibrinogen binding to the receptor, as well as factors
that return the receptor to the resting state. In platelets, agonist-
exposed fibrinogen-binding sites lose the capacity to bind over
time, and the closure of sites can be enhanced by elevating intra-
platelet cyclic AMP levels [10]. Our results suggest that a lipid
environment stabilizes the resting state of the receptor. Thus
the disappearance of the fibrinogen-binding-competent form
of GP Ilb-Illa in agonist-treated platelets and RGD-treated
membranes/phospholipid vesicles may be the result of an intrinsic
ability of the receptor in a lipid environment to revert to the
resting state. In contrast, when activated with peptides, detergent-
solubilized GP Ilb-Illa does not spontaneously revert to a
resting state when inserted into phospholipid vesicles (Figure 12).
One explanation for these findings is that peptide binding to
detergent-solubilized GPIlb-Illa induces different or additional
conformational changes in the receptor that do not occur when
peptides bind to GP Ilb-Illa in platelet membranes or in
phospholipid vesicles. Alternatively, we cannot exclude the
possibility that, in intact platelets as well as in platelet membranes
and phospholipid vesicles containing purified GPIlb-Illa, ad-
ditional unidentified regulatory factors act upon GPIlb-Illa to
return the receptor to the resting state. In this scenario, the
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peptide-activated form of detergent solubilized GP lIb-Illa
could be maintained following incorporation into phospholipid
vesicles if peptide binding to solubilized GP Ilb-IIIa released a
negative regulatory factor. Loss of a factor during vesicle
formation could account for the retention of the activated state
of GP Ilb-Illa. In this regard, O'Toole et al. [17] demonstrated
that the cytoplasmic domain of GP Ilb is required to maintain
the receptor in the resting state in intact cells and suggested that
this region of GP Ilb interacts with an intracellular regulatory
moiety which controls the affinity state of the receptor.
In summary, we have found that '25I-fibrinogen binds with
high affinity to a single class of sites in isolated platelet
membranes, presumably GP Ilb-Illa. However, the fibrinogen-
binding capacity represents only a fraction of the total GP
Ilb-Illa in the membranes. Fibrinogen binding can be enhanced
by pretreatment of the membranes with either the serine pro-
teinase chymotrypsin or a GP Ilb-Illa activating mAb. Platelet
activators, including agonists, G-protein activators and PKC, do
not stimulate fibrinogen binding, suggesting that one or more
cytosolic regulatory components may be lost during the mem-
brane isolation procedure. Platelet membranes possess the
ability to bind substantial amounts of YRGDS, and the maximal
binding capacity for YRGDS is similar to the total amount of
GP Ilb-Illa. Binding of RGD peptides to GP Ilb-Illa appears
to convert the receptor into a ligand-binding-competent state
that can be retained by membrane fixation but which is reversed
in the absence of fixation. Thus the low levels of fibrinogen
binding to the membranes could be explained by an absence of
a GP Ilb-Illa activating factor and/or the presence of a GP
Ilb-Illa repressing activity. Our data suggest that a lipid
environment may be one mechanism that stabilizes the resting
state of the receptor. Further investigations in this system may
provide direct evidence for the existence of factors which
modulate the affinity of GP Ilb-Illa for fibrinogen.
Activation of the fibrinogen-binding properties of GPIlb-Illa
represents a crucial step in the process of platelet aggregation.
Understanding the molecular mechanisms that regulate this
event requires the development of experimental approaches for
evaluating the activity of GP Ilb-Illa. Shattil and Brass [51,52]
have characterized the exposure of binding sites on GP Ilb-Illa
in platelets permeabilized with saponin or complement proteins
for this purpose. The data presented here suggest that isolated
platelet membranes may provide another system in which
regulation of GP Ilb-Illa can be investigated. The ability to
examine the fibrinogen-binding capacity of purified platelet
membranes should allow for further dissection of the platelet
signalling events that are required for modulation of the affinity
state of GP Ilb-4i1a.
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